Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) COO Sells $1,024,140.80 in Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) COO Jeremy Chadwick sold 12,905 shares of Kymera Therapeutics stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $79.36, for a total value of $1,024,140.80. Following the completion of the transaction, the chief operating officer owned 48,297 shares in the company, valued at $3,832,849.92. This trade represents a 21.09% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kymera Therapeutics Price Performance

KYMR opened at $81.42 on Friday. The business’s 50-day moving average is $83.33 and its two-hundred day moving average is $79.31. Kymera Therapeutics, Inc. has a 1 year low of $28.50 and a 1 year high of $103.00. The firm has a market capitalization of $6.70 billion, a PE ratio of -22.81 and a beta of 2.06.

Kymera Therapeutics (NASDAQ:KYMR) last posted its earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.89) by $0.18. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.The company had revenue of $34.37 million for the quarter, compared to analyst estimates of $8.27 million. During the same quarter in the previous year, the firm earned ($0.82) earnings per share. The firm’s quarterly revenue was up 55.5% compared to the same quarter last year. As a group, sell-side analysts expect that Kymera Therapeutics, Inc. will post -3.34 EPS for the current year.

Institutional Investors Weigh In On Kymera Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Smartleaf Asset Management LLC lifted its holdings in shares of Kymera Therapeutics by 382.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock worth $42,000 after purchasing an additional 424 shares during the period. Larson Financial Group LLC lifted its holdings in shares of Kymera Therapeutics by 81.5% during the third quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock worth $44,000 after purchasing an additional 349 shares during the period. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Kymera Therapeutics during the fourth quarter worth about $63,000. Bessemer Group Inc. lifted its holdings in shares of Kymera Therapeutics by 652.0% during the third quarter. Bessemer Group Inc. now owns 940 shares of the company’s stock worth $53,000 after purchasing an additional 815 shares during the period. Finally, Osaic Holdings Inc. lifted its holdings in shares of Kymera Therapeutics by 18,050.0% during the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock worth $48,000 after purchasing an additional 1,083 shares during the period.

Analysts Set New Price Targets

KYMR has been the topic of several analyst reports. Royal Bank Of Canada reiterated an “outperform” rating and issued a $108.00 target price on shares of Kymera Therapeutics in a research note on Thursday, February 26th. Citigroup lifted their target price on Kymera Therapeutics from $110.00 to $120.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Kymera Therapeutics in a research note on Tuesday, April 21st. Morgan Stanley restated an “overweight” rating and set a $119.00 price target on shares of Kymera Therapeutics in a research note on Thursday, April 30th. Finally, Stephens boosted their price target on Kymera Therapeutics from $95.00 to $100.00 and gave the stock an “overweight” rating in a research note on Monday, March 2nd. One equities research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $118.10.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.